The results of recent clinical trials of medicinal cannabinoid drugs show that dizziness and vertigo are commonly reported adverse side-effects. Cannabinoid CB1 receptors were initially thought to be expressedin very low densities in the vestibular nucleus complex (VNC). Recent immunohistochemical studies have challenged this idea and suggested that CB1 receptors may exist in numbers similar to the granule cell layer of the cerebellum. This, together with evidence that brainstem CB1 receptors have a higher efficacy than those in many other parts of the brain and that application of cannabinoids can elicit potent electrophysiological effects in VNC neurons, suggests that CB1 receptors and their endogenous ligands may be important in central vestibular function. In this review, we consider the potential clinical significance of the endocannabinoid system for the development of vestibular disorders, the effects of recreational cannabis use and the therapeutic use of medicinal cannabinoids.

Keywords:
Cannabinoid drugs, Endocannabinoid system, Central vestibular function, Vestibular nucleus complex
1.
Alger BE: Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002;68:247–286.
2.
Ashton JC, Friberg D, Darlington CL, Smith PF: Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett, in press.
3.
Ashton JC, Zheng Y, Liu P, et al: Immunohistochemical characterization and localization of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and effects of unilateral vestibular deafferentation. Brain Res 2004;1021:266–273.
4.
Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299–306.
5.
Bidaut-Russell M, Devane WA, Howlett AC: Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem 1990;55:21–26.
6.
Brady CM, Das Gupta R, Dalton C, et al: An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425–433.
7.
Breivogel CS, Sim LJ, Childers SR: Regional differences in cannabinoid receptor/G protein coupling in rat brain. J Pharmacol Exp Ther 1997;282:1632–1642.
8.
Caufield MP, Brown DA: Cannabinoid receptor agonists inhibit calcium current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992;106:231–232.
9.
Dell’Osso LF, Schon F, Hart P, et al: Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 2000;54:2190–2191.
10.
Devane WA, Dysarz FA, Johnson MR, et al: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605–613.
11.
Devane WA, Hanus L, Breuer A, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–1949.
12.
Di Marzo V, Fontana A, Cadas H, et al: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686–691.
13.
Egertova M, Elphick MR: Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol 2000;422:159–171.
14.
Elphick MR, Egertova M: The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond Ser B Biol Sci 2001;356:381–408.
15.
Glass M, Dragunow M, Faull RLM: Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997;77:299–318.
16.
Grassi S, Pettorossi VE: Synaptic plasticity in the medial vestibular nuclei: role of glutamate receptors and retrograde messengers in rat brainstem slices. Prog Neurobiol 2000;64:527–553.
17.
Guy GW, Flint ME: A single centre, placebo-controlled, four period, crossover tolerability study assessing pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901). J Cannabis Ther 2003a;3/4:35–77.
18.
Guy GW, Flint ME: A phase I, double-blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Ther 2003b;3/4:121–152.
19.
Herkenham M, Lynn AB, Little MD, et al: Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87:1932–1936.
20.
Herkenham M, Lynn AB, Johnson MR, et al: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563–583.
21.
Hoffman AF, Lupica CR: Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 2000;20:2470–2479.
22.
Howlett AC: Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 1984;35:1803–1810.
23.
Howlett AC, Fleming RM: Cannabinoid inhibition of adenylate cyclase – Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984;26:532–538.
24.
Karst M, Salim K, Burstein S, et al: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled study. JAMA 2003;290:1757–1762.
25.
Kreitzer AC, Regehr WG: Retrograde signalling by endocannabinoids. Curr Opin Neurobiol 2002;12:324–330.
26.
Levenes C, Daniel H, Soubrie P, et al: Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (Lond) 1998;510:867–879.
27.
Lutz B: On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 2004;68:1691–1698.
28.
Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma cells. Proc Natl Acad Sci USA 1992;89:3825–3829.
29.
Mailleux P, Vanderhaeghen JJ: Distribution of neuronal cannabinoid receptor in the adult brain: a comparative receptor binding autoradiography and in situ hybridization histochemistry. Neuroscience 1992;48:655–668.
30.
Marsicano G, Goodneough S, Monory K, et al: CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302:65–67.
31.
Matsuda LA, Lolait SJ, Brownstein MJ, et al: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–564.
32.
Mechoulam R, Fride E, Di Marzo V: Endocannabinoids. Eur J Pharmacol 1998;359:1–18.
33.
Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–65.
34.
Nakatsuka T, Chen H-X, Roper SN, et al: Cannabinoid receptor-1 activation suppresses inhibitory synaptic activity in human dentate gyrus. Neuropharmacology 2003;45:116–121.
35.
Newsham-West D, Darlington CL, Smith P: Potent effects of a selective cannabinoid receptor agonist on some guinea pig medial vestibular nucleus neurons. Eur J Pharmacol 1998;348:R1–R2.
36.
Pettit DA, Harrison MP, Olson JM, et al: Immunohistochemical localisation of the neural cannabinoid receptor in rat brain. J Neurosci Res 1998;51:391–402.
37.
Randall MD, Kendall DA, O’Sullivan S: The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004;142:20–26.
38.
Romero J, Hillard CJ, Calero M, et al: Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Mol Brain Res 2002;100:85–93.
39.
Schon F, Hart E, Hodgson TL, et al: Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999;53:2209–2210.
40.
Smith PF: Sativex (GW-1000). Curr Opin Invest Drugs 2004;5:748–754.
41.
Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. Br Med J 2004;329:253–261.
42.
Thomas BF, Adams IB, Mascarella W, et al: Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J Med Chem 1996;39:471–479.
43.
Van Sickle MD, Duncan M, Kingsley PJ, et al: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329–332.
44.
Van Sickle MD, Oland LD, Ho W, et al: Cannabinoids inhibit emesis through cannabinoid CB1 receptors in the brainstem of the ferret. Gastroenterology 2001;121:767–774.
45.
Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417–424.
46.
Vaughan CW, Connor M, Bagley EE, et al: Actions of cannabinoids on membrane properties and synaptic transmission in rat periacqueductal gray neurons in vitro. Mol Pharmacol 2000;57:288–295.
47.
Wade DT, Makela P, Robson P, et al: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434–441.
48.
Wilson RI, Kunos G, Nicoll RA: Presynaptic specificity of endocannabinoid signalling in the hippocampus. Neuron 2001;31:453–462.
49.
Zajicek J, Fox P, Sanders H, et al: Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trial. Lancet 2003;362:1517–1526.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.